Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names

@inproceedings{Chao2015NomenclatureAT,
  title={Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names},
  author={Jingdong Chao and Martha Skup and Emily Alexander and Namita Tundia and Dendy S Macaulay and Eric Qiong Wu and Parvez M. Mulani},
  booktitle={Advances in therapy},
  year={2015}
}
INTRODUCTION The purpose of the present study was to investigate the traceability of adverse events (AEs) for branded and generic drugs with identical nonproprietary names and to consider potential implications for the traceability of AEs for branded and biosimilar biologics. METHODS Adverse event reports in the Food and Drug Administration AE Reporting… CONTINUE READING